SLC5A2 and type 2 diabetes mellitus: Body weight loss with dapagliflozin, a first‐in‐class highly selective SGLT2 inhibitor, is consistently observed among patients with T2D receiving oral dapagliflozin 10 mg once daily as monotherapy12 or with additional glucose‐lowering therapies.13, 14, 15, 16, 17, 18 Mean body weight loss versus placebo, estimated from a network meta‐analysis, is −2.2 kg over 24 weeks,19 mostly accounted for by decreased body fat mass.14 Clinical data over 2 years show that body weight reduction with dapagliflozin 10 mg once daily is maintained.20